Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations
Cancer Reports · 2024
DOI: 10.1002/cnr2.2164 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2024. Verfasst von Isabella Wilson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia. Hauptthemen laut MEDLINE: Oncogene Proteins, Fusion, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Anaplastic Lymphoma Kinase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anaplastic lymphoma kinase ( ALK ) rearrangements are rare in non‐myofibroblastic sarcoma and there is limited data on the efficacy of ALK tyrosine kinase inhibitors (TKIs) and mechanisms of resistance in these patients. Case A 58 year‐old man with metastatic non‐myofibroblastic sarcoma was found to have an EML4‐ALK fusion on molecular sequencing. After progression on first line systemic therapy with doxorubicin, the patient received alectinib, a second generation ALK inhibitor, and had a marked clinical and radiological response. He progressed after 5 months of treatment. Repeat lung biopsy identified the emergence of an ALK I1171N resistance mutation. He was then treated with lorlatinib, again with rapid clinical improvement and significant partial radiological response. He progressed after 4 months, at which time a repeat lung biopsy identified a new ALK kinase domain mutation G1202R. The patient was subsequently treated with chemotherapy, though unfortunately died shortly after due to rapidly progressive disease.
Conclusion
This case report adds to a body of evidence demonstrating the potential transformative response to targeted therapy in non‐lung solid organ tumours harbouring ALK fusions. This is the first description tracking the development of resistance mutations in a patient with non‐myofibroblastic sarcoma and questions the utility of the presence of G1202R mutation as a marker of lorlatinib sensitivity in non‐lung ALK rearranged tumours, contrary to experience in lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
- Sydpath, St Vincent's Hospital, Sydney, Australia.
- St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
- Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia.
- Kinghorn Centre for Cancer Genomics Medicine, Garvan Institute of Medical Research, Sydney, Australia.
ORCID-Profile: Isabella Wilson
Zitieren
APA
Wilson, I., Qiu, M., Itchins, M., Wang, B., Huang, M. L., & Grimison, P. (2024). Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations. Cancer Reports. https://doi.org/10.1002/cnr2.2164
Vancouver
Wilson I, Qiu M, Itchins M, Wang B, Huang ML, Grimison P. Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations. Cancer Reports. 2024. doi:10.1002/cnr2.2164
BibTeX
@article{Wilson2024,
author = {Wilson, Isabella and Qiu, Min and Itchins, Malinda and Wang, Bin and Huang, Min Li and Grimison, Peter},
title = {Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.2164}
}
EUVIMED